Revolutionizing Depression Treatment: Novel Rapid-Acting Antidepressants & Emerging Drug Targets
Major depressive disorder (MDD) is a global health crisis affecting over 300 million people. While available antidepressants help some patients, treatment is far from satisfactory for many. Exciting research into rapid-acting agents like ketamine and psilocybin combined with exploration of novel drug targets finally offers real hope for transformational change in how depression is treated. …
